The study, conducted by Lan Xiong of the First People’s Hospital of Guangyuan in Sichuan, China, retrieved records from the Web of Science Core Collection and Scopus, merged and deduplicated them, and retained 3,332 publications for analysis. Roughly 94 percent were original research articles, a signal that the field remains driven by primary experimentation rather than consolidation. The growth curve is striking: annual output stayed below 100 papers per year before 2019, then accelerated sharply, exceeding 700 papers by 2025. The trajectory fits an exponential growth model with a coefficient of determination of 0.9442, a fit the author attributes largely to concurrent advances in artificial intelligence and the normalization of remote care.

The analytical machinery behind the mapping combined several established bibliometric tools. Microsoft Excel handled deduplication and annual trend summaries; VOSviewer 1.6.20 constructed co-authorship, co-citation and keyword co-occurrence networks; CiteSpace 6.4.R1 performed clustering, timeline visualization, centrality assessment and citation burst detection; and the bibliometrix R package computed source impact indicators such as the h-index, g-index and total citations. To make sure the underlying search was trustworthy, the author validated it against a benchmark cohort of eight highly relevant papers spanning continuous ambulatory tracking, freezing-of-gait detection and smartphone-based assessment; the query retrieved seven of the eight benchmark texts, a sensitivity of 87.5 percent across both databases.

The authorship landscape reveals how strongly the field is anchored by a small group of movement-disorder specialists. Martina Mancini of Oregon Health and Science University leads the rankings with 88 publications and 3,968 citations, followed closely by her longtime collaborator Fay Horak with 76 publications and 3,571 citations. Bastiaan Bloem of Radboud University, Jeffrey Hausdorff, Walter Maetzler, Lynn Rochester and Lori Chiari round out a dense collaborative network whose intellectual roots lie in quantitative gait analysis. Institutionally, Tel Aviv University emerges as the most prolific center with 123 articles, ahead of Oregon Health and Science University’s 101, with Radboud, the University of California System and Harvard forming prominent nodes in the collaboration network.

Geographically, the United States dominates, contributing 289 papers and 14,961 total citations, with China second at 206 publications; both nations accelerated notably after 2019. But the collaboration patterns differ in an instructive way. The U.S. and China show high proportions of single-country publications, reflecting strong independent domestic research bases, while European countries, particularly Italy, Germany and the United Kingdom, act as hubs of multinational collaboration. The author argues this reflects the demands of digital phenotyping itself: building robust sensor-based tools requires not only bioengineering expertise but also movement-disorder centers with well-characterized patient cohorts, a combination that European consortia have cultivated deliberately.

The journal analysis exposes a telling asymmetry at the heart of the field. Engineering venues dominate raw output: the journal Sensors alone published 311 of the 3,332 papers, followed by the Journal of Neuroengineering and Rehabilitation and a cluster of IEEE publications. Yet the most clinically influential journal, Movement Disorders, contributed fewer than 50 primary articles to the dataset while maintaining one of the highest citation impacts in the co-citation network. Dual-map overlay of citation flows confirms robust bridges between technical clusters, such as sensors, physics and bioengineering, and clinical domains like neurorehabilitation and movement disorders. In other words, technological feasibility is racing ahead while rigorous clinical validation in top-tier neurology journals remains comparatively scarce, and correspondingly precious.

The historiographic picture the study paints is one of three overlapping eras. The most-cited foundational papers, led by Shyamal Patel’s 2009 work on monitoring motor fluctuations with wearable sensors and Arash Salarian’s 2007 quantification of tremor and bradykinesia using an ambulatory monitoring system, established whether core Parkinsonian features could be measured reliably outside the exam room at all. Early keyword clusters centered on ambulatory monitoring, inertial signal acquisition and gait detection, with citation burst analysis showing the strongest early bursts for exactly those terms. From roughly 2015 to 2020, the emphasis shifted toward algorithms: support vector machines and other classifiers for detecting freezing of gait, falls and specific motor signs, evaluated through sensitivity, specificity and agreement with clinician ratings.

The most recent phase is unmistakably artificial intelligence. Keyword burst detection from 2024 through 2026 shows strong surges for artificial intelligence, digital biomarker and, perhaps most suggestively, local field potential. Deep learning models now attempt to translate continuous free-living sensor streams into clinically meaningful metrics, including remote estimation of MDS-UPDRS scores, and smartphone-based systems have reported promising performance for quantifying overall disease severity. At the same time, a prominent cluster around deep brain stimulation has risen alongside traditional kinematic assessment, pointing toward adaptive, closed-loop neuromodulation in which external kinematics fuse with internal brain signals to tailor stimulation dynamically to symptom fluctuations. The study cautions, however, that this frontier carries real technical hurdles, including real-time artifact rejection and multimodal data integration, and that its safety and long-term efficacy demand rigorous clinical validation.

Crucially, the analysis is explicit about what its maps do and do not prove. High publication volume signifies research enthusiasm and technical feasibility, not demonstrated clinical utility. Reported performance figures vary widely and resist direct comparison because studies differ in target symptoms, sensor configurations, datasets, reference standards, disease stages and validation strategies; a high accuracy figure from one laboratory cannot be assumed to generalize. Sensor-derived metrics are also highly susceptible to confounders, including disease stage, medication-induced fluctuations, comorbidities and even where the device sits on the body. The author therefore frames bibliometric prominence as evidence that concepts like digital biomarkers have become research priorities, not as evidence that they have achieved analytical validity, clinical validity or clinical utility, distinctions that regulatory initiatives such as digital endpoint qualification and the Critical Path for Parkinson’s Consortium are working to establish.

The roadmap that emerges from the study is less about building new gadgets and more about building trust. The author calls for standardized data collection and reporting protocols covering device placement, sampling frequency, preprocessing, task definitions and missing-data handling; multicenter real-world validation across diverse populations and medication cycles; and longitudinal studies that test whether digital measures actually track clinically meaningful change over time rather than merely agreeing with clinic-based scales at a single moment. Workflow integration is framed as the decisive bottleneck: clinicians need concise, interpretable summaries with uncertainty estimates rather than raw sensor streams, and patients need systems that minimize burden and protect privacy. Multimodal data fusion combining movement signals with physiology, imaging, electrophysiology and patient-reported outcomes, along with cautious exploration of closed-loop stimulation, marks the field’s higher-risk frontier. If the past twenty years were about proving sensors could see Parkinson’s disease in the wild, the next phase, on this evidence, will be about proving that what they see can safely change what doctors do.

Subject of Research: Bibliometric mapping of wearable sensor and digital health research in Parkinson's disease from 2005 to 2026

Article Title: Digital health meets Parkinson’s disease: a bibliometric exploration of wearable sensors research and emerging frontiers (2005–2026)

Article References: Xiong, L. (2026). Digital health meets Parkinson’s disease: a bibliometric exploration of wearable sensors research and emerging frontiers (2005–2026). Frontiers in Neuroinformatics, 20, Article 1937585. https://doi.org/10.3389/fninf.2026.1937585

Image Credits: AI Generated

DOI: 10.3389/fninf.2026.1937585

Keywords: Parkinson's disease, wearable sensors, digital biomarkers, bibliometric analysis, artificial intelligence, remote monitoring, freezing of gait, deep brain stimulation, machine learning, gait analysis, digital health, closed-loop neuromodulation

The technique in question is repetitive transcranial magnetic stimulation, or rTMS, a procedure in which rapidly pulsed magnetic fields are delivered through a coil held against the scalp. The magnetic pulses pass painlessly through the skull and induce small electrical currents in the underlying cortical tissue, nudging neurons toward greater or lesser activity depending on the stimulation parameters. Clinicians have long used rTMS targeting the primary motor cortex, the strip of brain tissue at the top of the head that commands voluntary movement, to treat a range of motor symptoms. What has remained frustratingly unclear is precisely how the stimulation remodels the brain’s locomotor circuitry when it is applied to freezing of gait, a symptom that does not respond to medication in the same way tremor or rigidity often do.

To answer that question, the research team assembled a carefully structured cohort. They enrolled 37 patients with Parkinson’s disease who experienced freezing of gait, 66 patients with Parkinson’s disease who did not, and 32 healthy controls. Every participant underwent a comprehensive baseline assessment, designated T0, combining transcranial magnetic stimulation paradigms with multimodal magnetic resonance imaging. This dual approach allowed the investigators to capture both the electrophysiological behavior of the cortex and the structural and functional architecture of the brain in the same individuals, on the same day, creating a detailed neurophysiological fingerprint of what distinguishes patients who freeze from those who do not.

The baseline findings were striking. Compared with both the non-freezing patients and the healthy controls, the freezing group showed decreased short-interval intracortical inhibition, a measure of how effectively inhibitory circuits within the motor cortex damp down excessive neural activity. In essence, the motor cortex of patients who freeze is running too hot, with its internal braking systems weakened. The same group also displayed excessive cortico-cortical coupling, meaning their motor cortex was functionally entangled with other cortical regions in an abnormally strong way, and reduced fractional anisotropy across extensive white matter bundles, a diffusion MRI marker indicating that the insulated fiber tracts connecting distant brain regions had lost structural integrity. Together, these three abnormalities paint a picture of a locomotor control system that is disinhibited, mis-wired, and structurally compromised.

With that baseline established, the researchers turned to treatment. The 37 patients with freezing of gait received ten add-on rTMS sessions targeting the lower limb region of the primary motor cortex, the portion of the motor map that controls the legs and feet. The stimulation protocol used a frequency of 10 hertz, meaning ten pulses per second, delivered at 90 percent of each patient’s resting motor threshold, the stimulation intensity calibrated individually to the minimum needed to evoke a measurable muscle response. Delivering high-frequency stimulation at this sub-maximal intensity is a standard approach for exciting the targeted cortex while keeping the procedure safe and tolerable. Because the sessions were added on top of existing care, the study could evaluate whether stimulation provided benefit beyond the patients’ usual treatment.

The results, measured one day after the final session and again at a one-month follow-up, showed meaningful improvements in objective gait indicators at both time points compared with baseline. This persistence is important: a therapy that only works for a few hours after the last session would be of limited clinical value, but the fact that gait measures remained improved a month later suggests that the stimulation produced changes that outlasted the treatment course itself. For a symptom that has historically been considered one of the most treatment-refractory features of Parkinson’s disease, the durability of the effect is a headline finding in its own right.

Just as importantly, the post-intervention assessments revealed what was happening inside the brain as patients improved. The team documented a constellation of neuromodulatory changes that partially reversed the abnormalities identified at baseline. Short-interval intracortical inhibition increased, indicating that the weakened inhibitory circuits within the motor cortex had been strengthened by the stimulation. Functional connectivity between the primary motor cortex and the occipital lobe, the visual processing region at the back of the brain, decreased, suggesting that the excessive cortico-cortical coupling seen before treatment had been dialed back. Perfusion, the blood supply reflecting neural activity, was reduced in the left precentral gyrus, the cortical region housing the motor representation of the body. And fractional anisotropy rose in the superior longitudinal fasciculus, a major white matter highway that links frontal, parietal, and temporal regions and plays a role in integrating motor planning with sensory feedback.

These mechanistic findings matter because freezing of gait has long resisted a simple explanation. It does not map cleanly onto the loss of dopamine that defines Parkinson’s disease, and it often persists even when other motor symptoms are well controlled by medication. The new data support a model in which freezing emerges from a network-level failure: a motor cortex that lacks adequate local inhibition, communicates abnormally with distant cortical areas including visual regions, and sits atop white matter pathways that can no longer relay signals efficiently. By strengthening cortical inhibition, normalizing the motor-occipital loop, reducing excessive perfusion, and remodeling the microstructure of key fiber tracts, rTMS appears to push this dysfunctional network back toward a healthier operating state.

The study also demonstrates the power of combining electrophysiology with multimodal imaging in a single experimental design. Transcranial magnetic stimulation paradigms provide a direct, quantitative readout of cortical circuit behavior in living humans, while diffusion and functional MRI reveal the structural scaffolding and functional coordination of the wider network. Measuring both before and after intervention allowed the researchers to link symptom change to specific, measurable neural mechanisms rather than relying on subjective reports alone. This kind of mechanistic transparency is increasingly seen as essential for moving brain stimulation from an empirical trial-and-error therapy toward a rationally targeted intervention.

There are, of course, limits to what a single study can establish. The intervention was evaluated in a defined cohort, and the authors note that the modulation of the identified abnormalities was partial rather than complete, meaning that stimulation improved but did not fully normalize the network disturbances underlying freezing. Larger and longer studies will be needed to determine optimal stimulation parameters, identify which patients are most likely to benefit, and confirm how long the effects can be sustained with maintenance treatment. Nevertheless, the work represents a significant step forward. It validates the primary motor cortex as a stimulation target for freezing of gait, identifies the cortical, connectivity, perfusion, and white matter changes that accompany clinical improvement, and offers a mechanistic framework that could guide the next generation of neuromodulation trials for one of Parkinson’s disease’s most feared symptoms.

Subject of Research: Neuromodulatory effects of repetitive transcranial magnetic stimulation on freezing of gait in Parkinson's disease

Article Title: Neuromodulatory mechanism of repetitive transcranial magnetic stimulation for freezing of gait in Parkinson’s disease

Article References: Gan, C., Sun, H., Cao, X., Si, Q., Wan, C., Ye, S., Shan, A., Gao, M., Shi, J., Wang, X., Ge, Y., Yuan, Y., Kong, Y., & Zhang, K. (2026). Neuromodulatory mechanism of repetitive transcranial magnetic stimulation for freezing of gait in Parkinson’s disease. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02800-7

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02800-7

Keywords: Parkinson's disease, freezing of gait, transcranial magnetic stimulation, primary motor cortex, cortical excitability, multimodal MRI, white matter integrity, brain stimulation, neuromodulation, movement disorders, gait analysis, neurology

The research team, led by clinicians and computational scientists at the University Hospital Würzburg together with collaborators at Charité – Universitätsmedizin Berlin, followed 100 people with Parkinson’s disease who underwent subthalamic deep brain stimulation between 2010 and 2020. The patients, whose average age at surgery was just over 60 years, underwent detailed assessments before the operation, again one year afterward, and in a subset of 33 patients, at three to five years after surgery. Rather than examining each symptom in isolation, the investigators deployed a battery of statistical tools, including unsupervised clustering, principal component analysis, and moderation models, to capture the joint structure of motor, cognitive, and mood symptoms as they evolved over time. The goal was to see whether deep brain stimulation preserves or reshapes the hidden architecture of the disease, and whether non-motor burden could explain why some patients regain mobility while others do not.

The technical pipeline was deliberately conservative. Missing clinical values were imputed using chained equations fitted only on pre-operative data, so that follow-up information could not leak backward and bias the baseline picture. Principal component analysis was fitted exclusively on the pre-surgery scores, and every follow-up visit was then projected into that fixed baseline space, allowing the researchers to track each patient’s trajectory along stable clinical dimensions rather than comparing shifting mathematical axes. Cluster stability was verified with 500 bootstrap resamples, and the robustness of the two-cluster solution was confirmed across 20 multiply-imputed datasets, with a mean adjusted Rand index of 0.945 against the primary solution. P values were corrected for false discovery across all simultaneous comparisons, and heteroscedasticity-consistent standard errors guarded the moderation models against uneven variance.

The first striking result concerned how patients group together before surgery. Unsupervised clustering of 22 clinical sub-domain scores revealed two reproducible profiles, a higher-impairment and a lower-impairment group, separated primarily by axial motor features: postural instability, gait, posture, and mobility, with smaller but meaningful differences in anxiety and depressive symptoms. The separation between clusters was large by conventional standards, with Cohen’s d values approaching or exceeding 1.9 for postural instability and gait. When the researchers projected the one-year post-operative assessments into this baseline cluster space, 84 percent of the patients who had started in the higher-impairment profile moved into the lower-impairment profile, while 95 percent of those who began in the lower-impairment group stayed there. Because the two profiles sit along a continuous severity dimension rather than representing truly distinct disease subtypes, the authors interpret this migration as improvement along a single axis of clinical burden, a continuous slide toward wellness that mirrors the well-documented efficacy of the stimulation itself.

The second major finding is perhaps the most sobering. Across every timepoint, the single largest source of between-patient clinical variance was a core motor triad: gait, mobility, and freezing of gait. This component explained 35 percent of the variance before surgery, 32 percent at one year, and still 28 percent at three to five years, and it was the only component to survive a rigorous permutation null, meaning that the other axes of variation were largely domain-specific and statistically fragile. In plain terms, even after electrodes have silenced tremor and rigidity, the way a patient walks remains the dominant thing that separates one person with Parkinson’s from another. This aligns with a growing body of evidence that axial symptoms, which depend on brainstem and cholinergic circuits as much as on the dopaminergic pathways that stimulation modulates, respond poorly to subthalamic stimulation and remain the leading source of unmet expectations after surgery.

The longitudinal projections added a temporal dimension to this picture. The motor severity axis dropped significantly in the first year after surgery, consistent with genuine motor improvement, but by three to five years it had drifted back toward baseline, echoing earlier reports of initial gait gains of more than 40 percent followed by substantial long-term decline. Meanwhile, a memory-dominated component, which captured 17 percent of between-patient variance at baseline, rose to 24 percent by the long-term follow-up, and within-patient projected memory scores increased significantly over the same interval. Mood features showed no significant change at one year but a small, statistically significant worsening at three to five years. The researchers are careful to note that these shifts reflect changes in relative heterogeneity and domain-specific burden rather than a wholesale reorganization of the disease, and that the covariance structure itself, tested with Procrustes analysis against 5,000 permutations, remained significantly aligned across timepoints.

The third and most clinically provocative finding emerged from the moderation analysis. Using analysis of covariance models that regressed each one-year motor outcome on its baseline value, a non-motor moderator, and their interaction, while adjusting for age and disease duration, the team asked whether pre-operative mood and cognition shaped the degree of motor recovery. The answer, in exploratory analyses, was yes. Higher baseline non-motor burden predicted poorer recovery of the composite gait-and-mobility triad, with an interaction coefficient of 1.45. Decomposed into individual features, the strongest culprits were psychomotor depressive symptoms, with a coefficient of 2.16, psychosomatic depressive symptoms, and language function, each associated with smaller mobility gains. Worse baseline orientation, by contrast, was associated with greater improvement. At the one-year follow-up, anxiety measured at the same visit showed a concurrent association with both the composite motor score and mobility, with coefficients of 2.30 and 2.81 respectively. Gait and freezing of gait themselves showed no significant moderators after correction, suggesting that the mood effect is concentrated in mobility rather than in freezing episodes.

Why would depression and anxiety written into a patient’s chart before surgery echo through their walking a year after electrodes are implanted? The authors point to the anatomy of the subthalamic nucleus itself, which is not a purely motor relay but a hub of striato-thalamo-cortical circuits serving cognitive and limbic functions as well. Gait and postural control demand constant cognitive-motor integration, the very faculty that frontal-executive dysfunction erodes, and symptom-specific tractography work has shown that axial motor symptoms are mediated by distinct white matter pathways connecting the subthalamic nucleus to the supplementary motor cortex and brainstem, rather than by the primary motor circuits that standard stimulation parameters most effectively engage. Shared prefrontal-subthalamic circuitry involved in both affective regulation and motor control offers a plausible substrate for the observed interactions, and some researchers have even proposed that patients implicitly trade cognitive performance for gait stability, a bargain that stimulation does not resolve.

The authors are appropriately cautious about how far these conclusions can be pushed. The study was retrospective, and strict inclusion criteria trimmed 180 consecutive patients down to 100, potentially selecting for more completely assessed cases. The long-term follow-up sample of 33 patients is modest, though comparable to other studies at equivalent timepoints, and that subset was enriched for higher baseline motor severity, which may have tempered the apparent long-term motor findings. The moderation analyses are explicitly exploratory, and no external cohort with harmonized multi-domain longitudinal data was available for validation, a scarcity the authors describe as a broader problem for the field. Medication changes were addressed through sensitivity analyses: levodopa equivalent daily dose fell by a median of 56.7 percent after surgery, but residualizing this change from every post-operative score left the component structure essentially untouched, with a Procrustes distance of just 0.004 between the original and adjusted solutions.

Even with those caveats, the clinical implications are hard to ignore. If pre-operative mood burden genuinely forecasts the size of a patient’s mobility recovery, then a psychiatric evaluation belongs in every deep brain stimulation candidacy discussion, not as a gatekeeping exercise but as a prognostic tool that helps patients and clinicians set realistic expectations. And if anxiety and psychosomatic symptoms at follow-up track concurrent motor burden, then post-operative mood monitoring, and interventions that combine motor rehabilitation with psychological support, such as dual-task training, become candidate levers for protecting the very gains that surgery was meant to deliver. The authors frame these as testable hypotheses for prospective multicenter trials rather than established determinants of outcome, but the direction of travel is clear: the future of deep brain stimulation may depend less on where the electrodes land than on how completely clinicians learn to read, and treat, the whole patient before and after the current flows.

Subject of Research: The relationship between non-motor symptom burden and motor recovery after subthalamic nucleus deep brain stimulation in Parkinson's disease

Article Title: Non-motor symptoms burden and motor recovery following STN–DBS in Parkinson's disease: a data-driven longitudinal analysis

Article References: Abbas, G., Peach, R., Temuulen, U., Tang, Y., Sil, T., Kufner, A., Endres, M., Volkmann, J., Lange, F., & Reich, M. (2026). Non-motor symptoms burden and motor recovery following STN–DBS in Parkinson's disease: a data-driven longitudinal analysis. Journal of Neurology, 273(10), Article 636. https://doi.org/10.1007/s00415-026-14160-x

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14160-x

Keywords: Parkinson's disease, deep brain stimulation, subthalamic nucleus, non-motor symptoms, gait, freezing of gait, mobility, depression, anxiety, principal component analysis, longitudinal study, neurology

The research, led by Matthew Leedom and Arun Singh of the University of South Dakota together with colleagues at Oregon Health & Science University and other institutions, analyzed resting-state electroencephalography recordings from 237 participants across three study sites. The cohort included 88 healthy controls and 149 people with Parkinson’s disease, all assessed in their clinically defined ON-medication state while taking their usual dopaminergic medication. Among the patients, 73 experienced freezing of gait and 76 did not, allowing the team to ask a deceptively simple question: do the brains of people with Parkinson’s, and specifically those with freezing, generate neural rhythms differently?

To answer it, the researchers abandoned the traditional approach of measuring average spectral power. Conventional EEG analysis averages oscillatory activity over time, which can obscure the fact that brain rhythms do not behave like continuous signals. Beta activity, the frequency range most closely tied to Parkinson’s motor symptoms, actually arrives in short, intermittent packets known as bursts. By detecting these bursts directly, the team could quantify how often they occurred, how long they lasted, how strong they were, and how much of the recording time the brain spent in a burst state, metrics that capture the temporal architecture of neural synchrony rather than its blunt average.

The technical execution was carefully harmonized. Because the three sites used different EEG systems with different sampling rates, the analysis was restricted to a common set of 11 electrodes spanning frontal, central, parietal, and occipital regions. The primary focus fell on the midline fronto-central Cz electrode, a location relevant to lower limb control and gait. Signals were filtered into four frequency bands, theta from 4 to 8 hertz, alpha from 8 to 13 hertz, low beta from 13 to 20 hertz, and high beta from 20 to 30 hertz, and a burst was defined as any moment when the amplitude envelope of the filtered signal exceeded the 75th percentile threshold for that participant, channel, and band. Rigorous artifact removal, independent component analysis, and false discovery rate correction for multiple comparisons guarded against spurious findings.

The headline result was strikingly frequency-specific. People with Parkinson’s disease showed significantly altered low-beta burst dynamics at the mid-frontal region: their low-beta bursts were more frequent, but shorter in duration, compared with healthy controls. Both effects survived statistical correction, with corrected p-values of 0.004 for burst rate and duration. Crucially, burst amplitude and the total proportion of time spent in a burst did not differ between groups, indicating that the disease changes the temporal organization of beta activity, its rhythm of firing and resting, rather than simply cranking up oscillatory power. Exploratory topographic maps showed that these low-beta abnormalities extended beyond the mid-frontal electrode across several central and posterior channels, consistent with the idea that beta bursts are network-level events involving distributed cortical regions rather than isolated local oscillations.

That pattern contrasts intriguingly with earlier invasive findings. Recordings from the subthalamic nucleus, a deep brain target for stimulation therapy, have typically linked prolonged beta bursts to greater motor impairment, particularly when patients are off medication. The current cortical findings, gathered at rest while patients were medicated, instead suggest a fragmentation of beta activity, more bursts that terminate quickly, possibly reflecting dopaminergic modulation, residual disease-related dysfunction, or compensatory cortical reorganization. The authors are careful to note that without simultaneous cortical-subthalamic recordings or direct ON-OFF medication comparisons, the precise mechanism remains an open question.

When the team turned to freezing of gait, the picture changed. In three-group comparisons across healthy controls, patients without freezing, and patients with freezing, low-beta burst rate and duration differed across groups, but when the analysis was restricted to Parkinson’s patients alone and adjusted for disease duration and motor severity on the MDS-UPDRS scale, no significant differences emerged between those with and without freezing. In other words, the low-beta burst abnormalities appear to mark Parkinson’s disease and general motor-network dysfunction rather than freezing specifically. Some apparent freezing-related differences in the unadjusted data likely reflected the fact that patients with freezing tend to have longer disease duration and more severe motor symptoms.

Instead, the strongest signal tied to freezing came from an entirely different frequency band. Theta burst amplitude at the mid-frontal electrode correlated positively with freezing severity, measured with site-standardized questionnaire scores. Both the median theta burst amplitude and the 90th percentile amplitude, capturing the strongest theta events, showed significant correlations with severity, with Spearman’s rho of 0.22 and corrected p-values of 0.032 and 0.028 respectively. No beta-band metric survived correction in these severity analyses. This dissociation is physiologically compelling: theta activity in mid-frontal cortex has long been linked to cognitive control and conflict monitoring, and freezing episodes are most likely to occur in situations demanding heightened executive control, such as turning, navigating doorways, or dual-tasking. Elevated theta burst amplitude could reflect greater recruitment of cognitive control networks as a compensatory response to failing automatic motor control, or alternatively a maladaptive state of network instability and excessive conflict monitoring. Because the data were cross-sectional and collected at rest, the study cannot definitively distinguish between these interpretations.

The findings carry practical implications. Burst-based EEG metrics may serve as complementary biomarkers that capture aspects of Parkinson’s pathophysiology invisible to conventional spectral analysis. A low-beta burst timing signature could help characterize motor-network dysfunction, while theta burst amplitude might offer a continuous, quantitative index of the cognitive-motor burden underlying freezing severity, potentially useful for tracking disease progression or evaluating therapies. Notably, the continuous severity measure proved more sensitive than the categorical freezing-versus-non-freezing classification, hinting that neural dysfunction accumulates along a spectrum rather than switching on at a diagnostic threshold.

The study also has honest limitations. Harmonizing to 11 channels limited spatial resolution and ruled out source localization, resting-state recordings may miss the dynamic processes that unfold during actual walking and freezing episodes, and the timing of patients’ last medication dose was not uniformly standardized across sites, leaving open whether medication itself shaped the burst patterns. FOG severity was measured with different questionnaires at different sites, requiring within-site normalization, and the operational definition of bursts via an amplitude threshold, while consistent with prior work, should not be taken to represent discrete biological events in every instance. Still, the scale of the cohort, the multi-site harmonization, and the clean frequency-specific dissociation make this one of the most systematic examinations of cortical burst dynamics in Parkinson’s disease to date. The next step, the authors suggest, is to combine standardized medication manipulations, higher-density recordings, and tasks that provoke freezing in the laboratory, bringing science closer to the moment when the brain’s rhythm of rhythm itself explains why feet freeze.

Subject of Research: Frequency-specific EEG burst dynamics in Parkinson's disease and freezing of gait

Article Title: Frequency-Specific EEG burst dynamics in Parkinson’s Disease and freezing of gait

Article References: Frequency-Specific EEG burst dynamics in Parkinson’s Disease and freezing of gait. (n.d.). https://doi.org/10.1007/s00415-026-14149-6

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14149-6

Keywords: Parkinson's disease, freezing of gait, EEG, beta bursts, theta oscillations, neural oscillations, basal ganglia, motor networks, cognitive control, biomarkers, neurophysiology, Journal of Neurology

The study, titled ‘Managing the mental state’ to tackle anxiety-related freezing of gait in people with Parkinson’s disease, set out to test a proposition that is increasingly supported by neuroscience but has rarely been evaluated in such a direct, trial-based fashion: that freezing of gait is not purely a motor problem, and that interventions aimed at the emotional and cognitive machinery of the brain may therefore yield measurable benefits for walking. The researchers framed their approach around the observation that anxiety and freezing tend to travel together, with anxious arousal narrowing attention, disrupting the automatic flow of movement and making episodes more likely at precisely the moments when people with Parkinson’s can least afford them.

Freezing of gait affects a substantial proportion of people with Parkinson’s as the disease progresses, and its mechanisms remain only partially understood. Contemporary models describe it as arising from a breakdown in the neural circuits that normally allow walking to proceed on autopilot. In healthy individuals, gait is largely controlled by subcortical loops that require little conscious attention. Parkinson’s disease damages these loops, forcing patients to rely more heavily on deliberate, effortful control of stepping. That compensation works reasonably well in calm, open environments, but it collapses under pressure. When cognitive resources are consumed by worry, when a doorway or a crowd demands rapid navigation, or when the fear of freezing itself takes hold, the fragile control system is overwhelmed and the gait pattern fragments into the characteristic stuttering, shuffling or complete arrest that patients know so well.

Anxiety enters this picture at several levels. There is the situational anxiety of approaching a feared trigger, such as turning in a tight space or crossing a busy road. There is the anticipatory anxiety that builds as people begin to organize their lives around avoiding situations in which freezing might occur, a pattern that can shrink confidence and mobility over time. And there is the physiological arousal that accompanies anxious states — elevated heart rate, muscle tension and heightened vigilance — all of which alter the way the brain allocates attention to movement. Researchers have argued that this arousal effectively competes with the already-strained motor control resources of the Parkinsonian brain, lowering the threshold at which freezing is triggered.

If anxiety is a genuine driver of freezing rather than a mere byproduct, the reasoning goes, then teaching patients to manage that anxiety should reduce the frequency or severity of episodes. This is the hypothesis the randomized controlled trial was designed to test. Rather than focusing on the mechanics of stepping, as many gait rehabilitation programs do, the intervention centered on strategies for regulating the mental state: recognizing the early signs of anxious arousal, applying techniques to calm and refocus attention, and reframing the fear of freezing that can itself precipitate an episode. Participants were randomly assigned to receive the mental-state intervention or a comparison condition, allowing the researchers to separate the specific effects of the anxiety-focused approach from the general benefits of attention, practice and clinical contact.

The randomized design matters. Freezing of gait fluctuates naturally from day to day and responds strongly to context, expectation and environment, which makes uncontrolled observations notoriously unreliable. A patient who believes a therapy will help may walk more confidently, freeze less and attribute the change to the treatment, regardless of the treatment’s specific content. By randomly allocating participants and including a comparator, the trial aimed to isolate the true effect of managing the mental state from placebo responses, regression to the mean and the natural course of the disease. Such rigor is essential if anxiety-focused approaches are to earn a place alongside medication, deep brain stimulation and cueing strategies in the standard toolkit for gait problems in Parkinson’s.

The broader significance of the trial lies in what it says about the nature of Parkinson’s disease itself. For much of the twentieth century, Parkinson’s was understood primarily as a disorder of movement, defined by tremor, rigidity, slowness and postural instability. Research over recent decades has progressively widened that picture, revealing profound non-motor dimensions — sleep disturbance, loss of smell, cognitive change, depression and anxiety — that often precede the motor symptoms by years and shape quality of life at least as much. The recognition that anxiety is not simply an understandable reaction to a difficult diagnosis but a modifiable factor with a direct bearing on motor function represents a meaningful shift. It reframes the psychological life of the patient as part of the disease mechanism, and therefore as a legitimate target of treatment.

The trial also speaks to a practical reality of clinical care. Pharmacological options for freezing of gait are limited; dopaminergic medications help some patients some of the time, but freezing frequently persists or even worsens as the disease advances, and no drug is approved specifically for the symptom. Physiotherapy and cueing techniques — rhythmic auditory signals, visual targets on the floor, laser attachments to walking frames — offer genuine benefit by providing external rhythm and attentional anchors, yet they do not address the internal state that can override them. An approach that equips patients to regulate anxiety in the moment could, in principle, be combined with these existing strategies, giving people a layered set of defenses: environmental cues for the feet, mental strategies for the mind.

For patients and families, the message embedded in this research is one of agency. Freezing of gait can feel arbitrary and humiliating, an unpredictable betrayal by one’s own body. The idea that the mental state — the breath, the attention, the fearful anticipation — is not just a victim of freezing but a participant in it offers a handle on the problem. It suggests that the moments before an episode, when the heart begins to race and the mind fills with dread, are not merely a prelude but an intervention point. Learning to notice that moment, and to act on it, may be as therapeutically important as any exercise performed in a clinic.

Much remains to be established. The mechanisms linking anxiety to freezing are still being mapped, the durability of mental-state interventions over months and years is an open question, and the optimal way to integrate such training with medication and physical therapy has yet to be defined. But the trial marks a clear step in a direction that many in the field consider overdue: treating the person with Parkinson’s as an integrated system in which emotion, cognition and movement are inseparable. If managing the mental state proves to loosen the grip of freezing, it will validate a simple but powerful idea — that in Parkinson’s disease, the mind is not a bystander to the gait, but part of the machinery that keeps it moving.

Subject of Research: A randomized controlled trial of mental-state management to reduce anxiety-related freezing of gait in Parkinson's disease.

Article Title: ‘Managing the mental state’ to tackle anxiety-related freezing of gait in people with Parkinson’s disease: a randomized controlled trial

Article References: Vissers, G., Tosserams, A., Duits, A. A., Helmich, R. C., Bloem, B. R., Young, W. R., & Nonnekes, J. (2026). ‘Managing the mental state’ to tackle anxiety-related freezing of gait in people with Parkinson’s disease: a randomized controlled trial. npj Parkinson's Disease. https://doi.org/10.1038/s41531-026-01571-w

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01571-w

Keywords: Parkinson's disease, freezing of gait, anxiety, randomized controlled trial, gait rehabilitation, motor symptoms, mental state, npj Parkinson's Disease, neurodegeneration, clinical trial, movement disorders, anxiety management

Published in npj Parkinson’s Disease, the research investigates what the authors call a “state-dependent reconfiguration failure” of the basal forebrain–cortical gradient. The phrase describes a breakdown in the brain’s ability to dynamically alter its functional organization according to changing demands. Rather than operating as a fixed circuit, the brain continuously adjusts its internal hierarchy as a person rests, prepares to move, initiates an action, or responds to a challenging environment. The study suggests that this flexibility may be particularly vulnerable in patients who experience freezing.

The basal forebrain is a collection of structures located beneath the cerebral cortex that helps regulate arousal, attention, learning, motivation, and the selection of behavior. It includes regions involved in cholinergic signaling, in which neurons release the neurotransmitter acetylcholine, as well as networks that interact with dopamine and other chemical systems. These areas do not simply issue commands to the legs. Instead, they help determine which information deserves priority and whether the brain is prepared to initiate and sustain a goal-directed action.

The cortex, meanwhile, is organized along broad functional gradients. At one end of these gradients are areas involved in immediate sensory processing and motor control. At the other are association regions that integrate memory, attention, decision-making, and internal goals. This arrangement allows the brain to move between highly focused processing and more abstract, flexible forms of cognition. A healthy nervous system can reconfigure this balance as circumstances change. Walking through an empty hallway, for example, requires a different neural strategy from walking through a busy station or stepping over an obstacle.

Parkinson’s disease disrupts several of the systems that make this flexibility possible. The loss of dopamine-producing neurons in the substantia nigra is the best-known pathological feature, and it impairs the basal ganglia circuits responsible for selecting and scaling movement. Yet freezing of gait often cannot be explained by dopamine depletion alone. Many patients continue to experience freezing even when their other motor symptoms improve with dopaminergic medication. This has led researchers to examine additional networks, including the cholinergic basal forebrain, frontal attention systems, brainstem locomotor regions, and large-scale cortical networks.

The importance of the new work lies in its focus on brain state rather than on a single permanently damaged pathway. A person with Parkinson’s disease may be able to walk normally in one context and freeze moments later when asked to turn, divide attention, cross a narrow space, or respond to an unexpected cue. Such variability implies that the nervous system retains some capacity for movement but struggles to shift efficiently between competing modes of operation. The study’s central concept is that freezing may emerge when this transition fails—when the brain cannot properly reconfigure its internal gradient to support action under changing conditions.

This framework also helps explain why freezing is so strongly influenced by attention and environmental context. External cues such as floor markings, rhythmic sounds, or another person’s pacing can sometimes help a patient overcome an episode. These interventions may work by reducing the computational demands placed on impaired networks or by providing an alternative route for initiating movement. If basal forebrain–cortical coordination is unstable, a strong visual, auditory, or cognitive cue could temporarily supply the structure that the brain is unable to generate internally.

The findings may have implications beyond diagnosis. Current clinical assessments often measure walking speed, step length, balance, or the number of freezing episodes under standardized conditions. Those measures are valuable, but they may not capture the neural instability that appears only when a patient moves between states. A state-sensitive approach could encourage researchers to evaluate how the brain responds during preparation, initiation, turning, dual-task walking, and unexpected interruptions. It may also help explain why two patients with similar conventional motor scores can have dramatically different risks of falling and loss of independence.

The research could eventually influence treatment strategies aimed at restoring network flexibility rather than simply increasing dopamine. Potential directions include therapies that target cholinergic signaling, noninvasive brain stimulation, adaptive deep-brain stimulation, cognitive-motor training, and wearable systems that deliver cues when freezing is detected. Such applications remain prospective, and the study does not by itself establish a new treatment. Its contribution is more fundamental: it reframes freezing of gait as a failure of dynamic network coordination, connecting the symptom to the brain’s inability to reorganize itself in real time.

That shift in perspective may be especially valuable as Parkinson’s research moves toward individualized care. Freezing is not a single, uniform phenomenon; it can be triggered by different combinations of motor difficulty, attention, anxiety, sensory conflict, and environmental complexity. Understanding how basal forebrain and cortical systems interact across these conditions could provide a biological explanation for that diversity. The broader message is that movement depends not only on whether the brain possesses the necessary motor commands, but also on whether its large-scale networks can assemble those commands at the precise moment they are needed.

Subject of Research: State-dependent brain-network reconfiguration and freezing of gait in Parkinson’s disease.

Article Title: State-dependent reconfiguration failure of the basal forebrain-cortical gradient in Parkinson’s disease with freezing of gait.

Article References: Hou, M., Liu, C., Zhao, J. et al. “State-dependent reconfiguration failure of the basal forebrain-cortical gradient in Parkinson’s disease with freezing of gait.” npj Parkinson’s Disease (2026). https://doi.org/10.1038/s41531-026-01506-5

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01506-5

Keywords: Parkinson’s disease, freezing of gait, basal forebrain, cerebral cortex, brain networks, neural reconfiguration, cortical gradients, cholinergic signaling, motor control, neuroscience